Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial
Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial
复制标题
DOI：
10.1212/01.wnl.0000238518.34389.12
复制
发表时间：
2006-10-10
期刊：
影响因子：
9.9
通讯作者：
Klopstock, T.
中科院分区：
文献类型：
--
作者：
Bender, A.;Koch, W.;Klopstock, T.
线粒体功能障碍在帕金森病（PD）的发病机制中起着重要作用。肌酸（Cr）是一种在PD动物模型中发挥神经保护作用的致能化合物。我们对60例PD患者进行了为期2年的安慰剂对照随机临床试验。Cr改善了患者情绪，并导致多巴胺能治疗的剂量增加较小，但对整体统一帕金森病评定量表评分或多巴胺转运蛋白SPECT无影响。
Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.